2023
2023-05-31
Moberg Pharma AB (publ) today announces that the total number of shares in the company has decreased to 10,085,933 due to the completion of the previously announced reverse share split. The total number of shares in Moberg Pharma AB (publ) thus amounts to 10,085,933 and total number of votes amounts to 10,085,933 as of 31 May 2023.
2023-05-17
The Annual General Meeting in Moberg Pharma AB (publ) (“Moberg Pharma” or the “Company”) on 16 May 2023 resolved on a reverse share split, through which ten existing shares will be consolidated into one share (Sw: Sammanläggning 1:10). The Board of Directors was authorized by the Annual General Meeting to resolve on the record date for the reverse share split. The Board of Directors now resolved that the record date for the reverse share split will be 25 May 2023.
2023-05-16
STOCKHOLM, May 16[th], 2023. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2023-05-09
REGISTRATION PROCESS ONGOING, 120-DAY REPORT AND 145-DAY QUESTIONS RECEIVED
2023-04-18
Moberg Pharma´s Annual report for 2022 has been published and is available on www.mobergpharma.se
2023-04-05
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 16 May 2023 at 16:30 on the Company's premises on Gustavslundsvägen 42, 5[th] floor, 167 51 Bromma.
2023-03-09
STOCKHOLM, March 9[th], 2023, Moberg Pharma AB (OMX: MOB) today announces that Taisho Pharmaceutical Co., Ltd and Moberg Pharma terminate the license agreement for development, registration and commercialization of MOB-015 in Japan. Moberg Pharma regains full rights to the product in Japan and retains milestone revenues paid by Taisho.
2023-02-07
REGISTRATION PROCESS AND THE PHASE 3 STUDY ONGOING